

10th International Workshop on Waldenstrom's Macroglobulinemia

Program Agenda

Co-Chairs:

Lia Palomba M.D., Memorial Sloan Kettering Cancer Center, New York NY, USA

Richard Furman M.D., Cornell Weill Cornell Medicine, New York, NY, USA

Jorge Castillo M.D., Dana Farber Cancer Institute, Boston MA, USA

Steven Treon M.D., PhD., Dana Farber Cancer Institute, Boston MA, USA

Thursday, October 11, 2018

6:30am Registration and Coffee service

Session I **Genomics in the Diagnosis and Management of WM** *Roger Owen, Chair*

7:30am *How important is MYD88 mutation status for the diagnosis of WM?*

Roger Owen, Leeds Teaching Hospitals NHS Trust

7:45am *What is the role of MYD88 and CXCR4 mutations in the management of WM?*

Steven P. Treon, Dana Farber Cancer Institute, USA

8:00am *How should CXCR4 mutations be used in the treatment of WM patients?*

Jorge J. Castillo, Dana Farber Cancer Institute, USA

8:15am *Can cell-free DNA be used to assess mutation status in WM?*

Irene Ghobrial, Dana Farber Cancer Institute, USA

Session II **Predisposition to WM** *Marzia Varettoni, Chair*

8:30am *What IgM MGUS and smoldering WM patients are at risk for progression to active WM?*

Robert A. Kyle, Mayo Clinic, USA

8:45am *Is detection of mutated MYD88 associated with progression of IGM MGUS?*

- Marzia Varettoni, University of Pavia, Italy
- 9:00am *What genomic changes accompany transition of IgM MGUS to WM?*
Bruno Paiva, University of Pamplona, Spain
- 9:15am *What underlying genomics are responsible for familial WM?*
Mary McMaster, National Institutes of Health, USA
- 9:30am *Genetic predisposition to WM is associated with B-cell activation outside germinal center*
Helga Ogmundsdottir, University of Iceland, Iceland
- 9:45am *Is Agent Orange exposure associated with WM?*
Ola Landgren, Memorial Sloan Cancer Center, USA

10:00am Morning Refreshments

Session III **Disease Presentation in WM**
Pierre Morel, Chair

- 10:15am *How should patients with WM related peripheral neuropathy be evaluated?*
Shirley D'SA, University College London Hospitals NHS Trust, London UK
- 10:30am *What is the spectrum of presentation associated with anti-MAG antibodies?*
Juliette Svahn, University Hospital Lyon, France
- 10:45am *How should patients with Bing Neel Syndrome be evaluated?*
Monique Minnema, UMC Utrecht Cancer Center, The Netherlands
- 11:00am *When should plasmapheresis be used in the management of WM?*
Marvin Stone, University of Texas, USA

11:15am **Keynote Lecture**
The pathophysiology of IgM related neuropathy
Keynote Speaker: Eduardo Nobile-Orazio, University of Milan, Italy

11:30-12:45pm LUNCH

Session IV **Genomic Landscape of WM**
Nikhil Munshi, Chair

12:30pm *What are the important genomic findings in WM?*
Zachary Hunter, Dana Farber Cancer Institute, USA

12:45pm *Are losses in 6q important to WM growth and survival?*
ML Guerrero, Dana Farber Cancer Institute, USA

1:00pm *Do TP53 mutations impact outcome in WM?*
Stephanie Poulain, CHRU-Lille, France

1:15pm *What mutations accompany disease transformation in WM?*
Cristina Jimenez, University of Salamanca, Spain

1:30pm **Keynote Lecture**
Is there spatial genomic heterogeneity in plasma cell malignancies?
Keynote Speaker: Gareth Morgan, University of Arkansas, USA

1:45pm **Keynote Lecture**
Is genomic evolution predictable in plasma cell malignancies?
Keynote Speaker: Nikhil Munshi, Dana Farber Cancer Institute, USA

2:00pm Afternoon refreshments

Session V **Mechanisms of Tumor Growth and Survival in WM**
Douglas Joshua, Chair

2:15pm *How do MYD88 mutations impact WM cell growth and survival?*
Guang Yang, Dana Farber Cancer Institute, USA

2:30pm *Are MYD88 mutations by themselves sufficient to cause WM?*
Ruben Carrasco, Harvard Medical School, USA

2:45pm *Do genomics impact cytokine related signaling in WM?*
Josephine Vos, University of Amsterdam, The Netherlands

3:00pm *How does the microenvironment impact WM cell growth and drug resistance?*
ST Pals, University of Amsterdam, The Netherlands

3:15pm **Keynote Lecture**
Do exosomes play a role in propagating mutated MYD88 signaling?
Keynote Speaker: Roman Jerala, National Chemistry Institute, Slovenia

Session VI Oral Presentations I (Selected from Submitted Abstracts)

MJ Kersten and Zachary R. Hunter, Co-Chairs

3:30pm *MYD88 L265P mutation in IgM MGUS: Detection by droplet digital PCR*
Simone Ferrero, University of Torino, Italy

3:45pm *Progression risk-based classification of Asymptomatic WM*
Mark Bustoros, Dana Farber Cancer Institute, USA

4:00pm *Clonality Assessment of CXCR4 S338X predicts outcomes to ibrutinib in WM*
Joshua Gustine, Dana Farber Cancer Institute, USA

4:15pm Characterization of endogenous CXCR4 inhibitory peptides to target WM
LM Kaiser, Comprehensive Cancer Center of Ulm, Germany

4:30pm Day Adjournment

5:30-6:00pm **Departures from Lobby for Ferry Boats to Ellis Island**
(All attendees must clear security at Battery Park Embarkation)

6:30pm **OPENING CEREMONY AT ELLIS ISLAND**
Young Investigator Poster Presentations and Awards
Presentation of Robert A. Kyle Award
Welcome Dinner Reception

Friday, October 12, 2018

7:00am Registration and Coffee service

8:00am **Late Breaking Abstract Lecture**

Usefulness of time-dependent Cox model with cause-specific competing risk analyses for assessing prognosis during the course of Waldenström macroglobulinemia (WM).

Bénédicte Hivert, CHRU de Lille, France

Session VII **Clinical Trials in WM: Rituximab-based therapy**
Eva Kimby, Chair

8:15am *Bendamustine and Rituximab in treatment naïve patients with WM*

Veronique Leblond, Hospital Pitie-Salpetriere, France

8:30am *Long term efficacy of Rituximab in MAG positive peripheral neuropathy RIMAG study follow-up*

Jean Marc Leger, Hospital Pitié-Salpêtrière, France

8:45am *Randomized clinical trial of BCR vs. FCR in treatment naïve WM patients*

Rebecca Auer, University College of London, UK

9:00am **Keynote Lecture**

Is there a standard of care for treating treatment naïve WM?

Keynote Speaker: Adam Olszewski, Brown University, USA

9:15am Morning Refreshments

Session VIII **Clinical Trial Updates in WM: Proteasome Inhibitors**
Christian Buske, Chair

9:30am *Long term follow-up of Bortezomib, Dexamethasone & Rituximab in treatment-naïve WM*

Stathis Kastiris, University of Athens, Greece

9:45am *Long term follow-up of Carfilzomib, Dexamethasone, Rituximab in treatment-naïve WM*
Kirsten Meid, Dana Farber Cancer Institute, USA

10:00am *Prospective study of Carfilzomib in previously treated WM patients*
David Vesole, Hackensack Medical Center, USA

10:15am *Ixazomib, Dexamethasone, Rituximab in previously-treated WM patients*
M.J. Kersten, University of Amsterdam, The Netherlands

Session IX **Clinical Trials Updates in WM: Ibrutinib**
Lia Palomba, Chair

10:30am *Ibrutinib monotherapy in treatment-naïve WM patients*
Steven Treon, Dana Farber Cancer Institute, USA

10:45am *Long term follow-up of ibrutinib monotherapy in previously-treated WM patients:
Update of pivotal trial*
Ranjana Advani, Stanford University Medical Center, USA

11:00am *Ibrutinib monotherapy in rituximab-refractory WM patients*
Judith Trotman, University of Sydney, Australia

11:15am *Randomized study of ibrutinib/rituximab versus rituximab in symptomatic WM patients*
Meletios Dimopoulos, University of Athens, Greece

11:30-12:30pm LUNCH

Session X **Clinical Trials Updates in WM: Novel Agents and Trials in Progress**
Meletios Dimopoulos, Chair

12:30pm *Phase II Study of the BTK-inhibitor Acalabrutinib in previously-treated WM patients*
Rick Furman, Weill Cornell Medical College, USA

12:45pm *Phase II Study of the BTK-inhibitor Zanubrutinib in symptomatic WM patients*
Constantine Tam, University of Melbourne, Australia

- 1:00pm *Phase III Study of Zanubrutinib vs. Ibrutinib in symptomatic WM patients*
Jane Huang, Beigene, USA
- 1:15pm *Phase II Study of the BCL2-inhibitor Venetoclax in previously treated WM patients*
Jorge J. Castillo, Dana Farber Cancer Institute, USA
- 1:30pm *Phase I/II Study of CXCR4-inhibitor Ulocuplomab plus ibrutinib in symptomatic WM*
Steven P. Treon, Dana Farber Cancer Institute, USA
- 1:45pm *Phase II Study of the CD38-antibody Daratumumab in previously treated WM patients*
Jorge Castillo, Dana Farber Cancer Institute, USA

Session XI **Ibrutinib Resistance in WM**
Richard Furman, Chair

***** Afternoon refreshments will be served during the Session at the back of the Hall***

- 2:00pm *What mutations are associated with resistance to BTK-inhibitors in WM?*
Lian Xu, Dana Farber Cancer Institute, USA
- 2:15pm *What are the mechanisms of resistance to ibrutinib in WM?*
Guang Yang, Dana Farber Cancer Institute, USA
- 2:30pm *Does BCL2 play a role in ibrutinib resistance?*
Matt Davids, Dana Farber Cancer Institute, USA

2:45pm **Keynote Lecture**
Evolutional Landscape of Ibrutinib Resistance
Keynote Speaker: Dan Landau, Weill Cornell Medical College, USA

3:00pm **Keynote Lecture**
Understanding and overcoming ibrutinib resistance in B-cell malignancies
Keynote Speaker: Adrian Wiestner, National Institutes of Health, USA

Session XII Oral Presentations II (Selected from Submitted Abstracts)

Judy Trotman and Ranjana Advani, Co-Chairs

3:15pm *Development of novel IRAK1 inhibitors for treatment of WM*

Xia Liu, Dana Farber Cancer Institute

3:30pm *CANOMAD: Clinical, Biological, Electrophysiological and Treatment Analysis*

Marie Le Cann, CHU Hopital Pitie-Salpetriere, France

3:45pm *Ibrutinib Therapy in WM: Outcomes Outside a Clinical Trial*

J. Abeykoon, Mayo Clinic, USA

4:00pm *Phase II Study of Idelalisib and Obinutuzumab in relapsed/refractory WM*

C. Tomowiak, CHU de Poitiers, France

4:15pm *Phase II Study of Bendamustine, Rituximab, Bortezomib in relapsed/refractory WM*

G. Benevolo, Fondazione Italiana Linfomi ONLUS, Italy

4:30pm **POSTER PRESENTATIONS AND RECEPTION**

5:00-6:00pm **POSTER DISCUSSIONS**

Ranjana Advani and Marvin Stone, Co-Chairs

Incidence and inheritance of hyperphosphorylated paratag-7 in WM

L. Brandefors, Karolinska Institut, Sweden

Assessment of molecular response by RT-PCR for MYD88 L265P

I. Defrancesco, Fondazione IRCCS Policlinico San Matteo, Italy

Real Life Outcome of LPS and SMZL: Analysis of NF10 Project

L. Arcaini, University of Pavia, Italy

CD38 as a novel therapeutic target in WM

Paulus, Mayo Clinic Jacksonville, FL

Significance of residual neoplastic cells by flow cytometry in R2W Trial

Ruth de Tute, St. James Institute of Oncology, UK

7:00pm **FACULTY RECEPTION AND DINNER AT PIER A HARBOR HOUSE**

(By Invitation; Faculty Departs Lobby at 6:45pm)

Saturday, October 13, 2018

7:30am Registration and Coffee service

8:00am **Keynote Lecture**

What are the new targets for drug development in WM?

Keynote Speaker: Sara Buhrlage, Harvard Medical School, USA

Session XIII Specialized Treatment Approaches to WM
JP Fermand, Chair

8:15am *How should the WM patient with amyloidosis be cared for?*

Giampaolo Merlini, University of Pavia, Italy

8:30am *How should Bing Neel Syndrome be treated?*

Monique Minnema, UMC Utrecht Cancer Center, The Netherlands

8:45am *When is autologous transplant appropriate for WM patients?*

Charalampia Kyriakou, University College Hospital of London, UK

9:00am *In which WM patients is CAR-T-cell therapy appropriate?*

Lia Palomba, Memorial Sloan Cancer Center, USA

9:15am Morning Refreshments

Session XIV Panel Discussions on Treatment Approaches to WM
Veronique Leblond and Meletios Dimopoulos, Chairs

9:30am *Should MYD88 and CXCR4 mutation status impact treatment decision making?*

Roger Owen, MJ Kersten, Constantine Tam, Marzia Varettoni, Jorge Castillo

10:00am *What is the goal of therapy in WM: Complete Response or Disease Control?*

Stathis Kastritis, Lia Palomba, Alessandra Tedeschi, Roger Owen, Christian Buske,

10:30am *How do you manage ibrutinib related side effects and withdrawal syndrome?*

Jorge Castillo, Richard Furman, Ranjana Advani, Judith Trotman, Christian Buske,
Adrian Wiestner

- 11:00am *Should rituximab maintenance be offered to all patients?*
Ranjana Advani, Stathis Kastritis, Richard Furman, Judith Trotman, Eva Kimby
- 11:30am *What is the optimal treatment approach to IgM related peripheral neuropathy?*
Jorge Castillo, Eduardo Nobile-Orazio, Veronique LeBlond, Shirley D'Sa, JM Leger,
Juliette Svahn

12:00-1:00pm LUNCH

Session XV **Associated and Secondary Malignancy Risks in WM Patients**
Alessandra Tedeschi, Chair

- 1:00pm *Are WM patients at higher risk for treatment unrelated cancers?*
Jorge Castillo, Dana Farber Cancer Institute, USA
- 1:15pm *Should additional cancer screening measures be adopted for WM patients?*
Stathis Kastritis, University of Athens, Greece
- 1:30pm *Therapy-related myeloid neoplasms: Insights from UK R2W Trial*
R. Owen, St. James Institute of Oncology, UK
- 1:45pm *How important are treatment related secondary malignancies in WM?*
Alessandra Tedeschi, Niguarda Hospital, Italy

**** Afternoon refreshments will be served during the Session at the back of the Hall**

Session XVI **Consensus Panel Discussions**
Steven P. Treon and Meletios Dimopoulos, Co-Chairs

- 2:00pm *Diagnostic Markers in WM*
Discussants: J. Castillo/ S. Kastritis
- 2:30pm *Treatment Recommendations for WM and IgM Related Disorders*
Discussants: S. Treon/M. Dimopoulos

- 3:00pm *Priority Clinical Trials for WM*
Discussants: V. LeBlond/MJ Kersten
- 3:30pm Day Adjournment
- 5:00pm **Bus Departures from Lobby to United Nations Plaza**
- 6:00pm **CLOSING CEREMONY AT UNITED NATIONS**
(All attendees must clear security at UN Pavilion)
Tour of General Assembly and Security Council
Farewell Dinner Reception at United Nations Delegates Banquet Hall
Awards Ceremony
Presentation of Jan Gosta Waldenstrom Award
Presentation of WM Innovation Award
Presentation of WM Humanitarian Awards
Welcome to IWWM11